Daraxonrasib Doubles Survival in Pancreatic Cancer: Inside ASCO 2026’s Most Consequential Result

A Phase 3 trial just cut the risk of death by 60 percent in metastatic pancreatic cancer, a disease that has resisted nearly every therapeutic advance for four decades. The RAS revolution is no longer theoretical.

Presented By Our Partners

For forty years, scientists watched KRAS sit at the center of one of cancer’s most destructive engines, close enough to touch but impossible to disarm. Now, at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, a drug called daraxonrasib has delivered the clinical trial result that oncologists have been waiting decades to see: a 60 percent reduction in the risk of death for patients with previously treated metastatic pancreatic cancer, with a median overall survival of 13.2 months compared to 6.6 months for chemotherapy.

The study, the Phase 3 RASolute 302 trial, was presented during a plenary session at ASCO 2026 and simultaneously published in the New England Journal of Medicine. It is the first Phase 3 randomized controlled trial of a RAS(ON) multi-selective inhibitor in any cancer, and by every meaningful measure, it met its primary endpoints with room to spare.

“These results are landscape-changing for metastatic pancreatic cancer patients with a KRAS mutation. We are seeing unprecedented survival and efficacy in second-line treatment with an expected safety profile. The RAS revolution is here, and this study is proof of principle that targeting KRAS in pancreatic cancer is feasible and effective,” said Rachna Shroff, MD, MS, FASCO, Chief of the Division of Hematology and Oncology at the University of Arizona Cancer Center and an ASCO Expert in gastrointestinal cancers.

Why Pancreatic Cancer Has Always Been Different

Pancreatic ductal adenocarcinoma occupies a singular position in oncology: it is diagnosed late, spreads early, and has historically resisted almost every therapeutic advance. The American Cancer Society estimates that roughly 67,500 Americans will be diagnosed with pancreatic cancer in 2026. About 95 percent of those cases will be PDAC.

More than half of cases are already metastatic at the time of diagnosis. For those patients, the five-year relative survival rate sits at approximately 3 percent. First-line chemotherapy regimens, primarily FOLFIRINOX and gemcitabine plus nab-paclitaxel, can extend life by months. But when those regimens fail, the second-line options have been bleak: median progression-free survival of three to four months, median overall survival of six to seven months, and toxicities that often erode quality of life faster than the cancer itself.

The central reason for this therapeutic ceiling has always been KRAS. More than 90 percent of pancreatic cancers are driven by mutations in the KRAS gene, which encodes a protein that acts as a molecular switch for cell growth. When functioning normally, KRAS toggles on in response to growth signals, initiates cell division, then toggles off. In PDAC, the switch is stuck in the “on” position, forcing continuous unregulated proliferation.

Oncologists knew this since the early 1980s. The problem was that KRAS, in its active GTP-bound state, presents no obvious binding pocket for small molecules. For four decades, the target was considered undruggable, and the field worked around it rather than at it.

The First Cracks: Sotorasib, Adagrasib, and the Limits of Specificity

The wall began to crack in 2021, when the FDA approved sotorasib, developed by Amgen, as the first direct KRAS inhibitor. It was followed by adagrasib in 2022. Both drugs bind KRAS in its GDP-bound, inactive state and are specifically designed for a single mutation variant: KRAS G12C.

That specific variant matters in lung cancer, where KRAS G12C accounts for roughly 13 percent of adenocarcinomas. But in pancreatic cancer, KRAS G12C is vanishingly rare, present in only about 1 to 2 percent of cases. The dominant mutations in PDAC are G12D, G12V, G12R, and G12A, representing more than 95 percent of KRAS-driven pancreatic tumors.

Sotorasib and adagrasib offered nothing for these patients. What was needed was not a variant-specific inhibitor but a pan-RAS inhibitor capable of targeting the protein across its full mutational spectrum, and in its active, GTP-bound form. That is exactly what daraxonrasib was designed to do.

A New Class: The Molecular Glue That Stops RAS Cold

Daraxonrasib, developed by Revolution Medicines, represents a structurally distinct class of RAS inhibitor called a RAS(ON) multi-selective tri-complex inhibitor. Where earlier drugs target RAS in its inactive state, daraxonrasib targets the active, signaling-capable form of the protein.

Its mechanism involves what researchers describe as molecular glue. Daraxonrasib binds to a cellular chaperone protein called cyclophilin A. The resulting daraxonrasib-cyclophilin A complex then adheres to the active RAS protein, physically blocking the effector binding sites that RAS uses to transmit its growth signals downstream. Without those effector interactions, the oncogenic cascade stops.

Critically, this mechanism does not depend on any specific mutation. Daraxonrasib is effective against KRAS G12D, G12V, G12R, G13D, Q61H, and wild-type KRAS alike. That breadth of activity, combined with oral once-daily dosing, is what made it the candidate of choice for a randomized trial in PDAC, where the mutation spectrum is wide and treatment-naive variant profiling is not always comprehensive.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

RASolute 302: Trial Design and Population

The Phase 3 RASolute 302 clinical trial enrolled 500 patients across 59 sites in North America, Europe, and Asia. All participants had metastatic PDAC that had progressed on at least one prior line of therapy, most commonly gemcitabine-based regimens or FOLFIRINOX. Participants were required to have an ECOG Performance Status of 0 or 1, indicating they remained functional enough to tolerate active treatment. Median age was 66 years, and the study population was roughly evenly split between men and women.

Patients were randomized to receive either daraxonrasib orally once daily (248 patients) or investigator’s choice chemotherapy (252 patients). The chemotherapy arm reflected real-world second-line practice, allowing oncologists to select from approved regimens including nanoliposomal irinotecan plus fluorouracil, oxaliplatin-based regimens, or single-agent gemcitabine.

Of the 500 patients enrolled, 459 had tumors harboring RAS G12 variants, the dominant mutation category in PDAC. The remainder had G13 or Q61 variants, or wild-type RAS. The trial was designed to assess outcomes in both the RAS G12 population and the overall intent-to-treat population.

Lead investigator Brian Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, framed the trial’s ambition at the ASCO presentation: “Few therapies are available for patients with previously treated metastatic pancreatic cancer, and these therapies have modest efficacy and substantial toxicities. The RASolute 302 trial was designed to assess a RAS(ON) multi-selective inhibitor as a second-line treatment for patients with metastatic pancreatic cancer, looking to define a new standard of care for these patients that works better and has less side effects than currently available chemotherapies.”

The Numbers: A Survival Curve That Changed the Conversation

At a median follow-up of 8.5 months, the data were unambiguous.

Median overall survival in the daraxonrasib group reached 13.2 months, compared to 6.6 months in the RAS G12 chemotherapy subgroup and 6.7 months in the overall chemotherapy group. The hazard ratio for death was 0.40, representing a 60 percent reduction in the risk of death. The p-value was below 0.0001, far exceeding any reasonable threshold for statistical significance.

Progression-free survival mirrored the overall survival results. In the RAS G12 population, median PFS was 7.3 months for daraxonrasib versus 3.5 months for chemotherapy. In the overall population, the figures were 7.2 months versus 3.6 months.

The objective response rate in the daraxonrasib group was 33.2 percent for RAS G12 patients and 31.6 percent in the overall population. In the chemotherapy group, ORR was 11.8 percent and 11.2 percent respectively. Tumor shrinkage at a clinically meaningful level occurred in roughly one in three daraxonrasib patients, compared to roughly one in nine on chemotherapy.

The safety data reinforced the efficacy picture. Grade 3 or higher treatment-related adverse events occurred in 43.6 percent of patients in the daraxonrasib arm and 57.5 percent of those in the chemotherapy arm. Treatment discontinuation due to toxicity was 1.2 percent in the daraxonrasib group and 11.2 percent in the chemotherapy group. In a disease where quality of life during treatment matters profoundly, this safety differential carries real clinical weight.

Multiple oncologists at ASCO described the result as a “grand slam.” For a disease whose second-line standard of care has moved essentially sideways for years, the phrase was not hyperbole.

What Comes Next: FDA, Combinations, and the Broader Pipeline

Revolution Medicines has announced that data from RASolute 302 will be submitted to the FDA to support daraxonrasib’s application as a new drug for pancreatic cancer. Given the magnitude of the survival benefit and the depth of unmet need in this population, the drug is widely expected to receive priority review, which would shorten the standard 10-month review timeline to roughly six months.

If approved, daraxonrasib would represent the first molecularly targeted second-line treatment for PDAC to demonstrate a survival benefit over chemotherapy in a Phase 3 randomized controlled trial. That designation would make it a genuine new standard of care, the first in this setting since nanoliposomal irinotecan received approval in 2015.

Clinical trials testing daraxonrasib in additional settings are already underway. Revolution Medicines has initiated studies evaluating the drug as first-line treatment for PDAC, and trials in other RAS-driven cancers, including colorectal and lung cancer, are in progress. Researchers are also studying resistance mechanisms. Early data point to secondary KRAS amplification and bypass pathway activation through receptor tyrosine kinases as likely escape routes, and combination strategies with MEK inhibitors and EGFR antibodies are being evaluated to address them.

The publication of Phase 1/2 daraxonrasib data in the New England Journal of Medicine earlier in May 2026, co-authored by Dr. Wolpin and colleagues, provided the foundational evidence that RASolute 302 expanded upon at scale. Together, the two publications represent the most complete evidence package ever assembled for a RAS-targeted therapy in pancreatic cancer.

The Broader Significance: RAS as Oncology’s New Frontier

The daraxonrasib story is not an isolated drug approval. It represents the convergence of structural biology, computational chemistry, and precision clinical design that finally cracked a target that resisted all comers for four decades.

KRAS mutations are found in approximately 25 percent of all human cancers. Lung, colorectal, and pancreatic cancers account for the largest volumes, but RAS-driven tumors extend into endometrial, ovarian, bladder, and biliary tract cancers as well. A pan-RAS inhibitor with daraxonrasib’s efficacy profile has, in principle, relevance across that entire landscape.

For patients with KRAS-mutated colorectal cancer, where G12C inhibitors have shown modest single-agent activity, pan-RAS approaches combined with EGFR blockade are among the most closely watched programs in the field. For biliary tract cancers, where KRAS G12D is prevalent, early-phase data with daraxonrasib and related molecules are generating real momentum. The RASolute 302 results in pancreatic cancer will accelerate investment across all of these tumor types.

Rachna Shroff said it plainly at ASCO: “The RAS revolution is here.” That statement was addressed to an audience of oncologists treating pancreatic cancer, but its meaning extends considerably further.

What This Means For You

Most people reading this will not have a pancreatic cancer diagnosis. That distance from the disease is worth examining, because it creates space for both prevention and preparedness.

Within the Five Pillars framework, the daraxonrasib result sits at the intersection of what we can control today and what medicine can do for us when we reach tomorrow’s therapeutics. The foundational argument for nutrition, movement, sleep, breathwork, and cognitive resilience, the four fundamentals and mindset practices that Healthcare Discovery is built around, is not that they prevent every disease. It is that they compress the window of vulnerability and extend the biological runway that gives therapeutic advances like daraxonrasib a chance to matter.

For pancreatic cancer specifically, the modifiable risk factor evidence points clearly toward metabolic health. Tobacco smoking accounts for approximately 25 percent of PDAC cases and remains the single most actionable preventive target. Chronic metabolic dysfunction, particularly the hyperinsulinemia associated with type 2 diabetes and insulin resistance driven by refined carbohydrates and sedentary behavior, is increasingly implicated in pancreatic cancer risk. A 2022 pooled analysis published in JAMA Oncology found that individuals with the highest dietary inflammatory scores had significantly elevated risk of PDAC. The Nurses’ Health Study and the Health Professionals Follow-Up Study have both found that vigorous physical activity is inversely associated with pancreatic cancer incidence.

None of this is a guarantee. Pancreatic cancer also strikes people who eat well, exercise consistently, and never smoke, often because of inherited variants in BRCA2, PALB2, ATM, or PRSS1 that silently elevate lifetime risk. For individuals with a family history of pancreatic cancer or a known germline predisposition, endoscopic ultrasound surveillance coordinated through academic medical centers has become the standard of care for early detection.

But for the patients who do receive a metastatic PDAC diagnosis, the world is measurably different today than it was six months ago. The shift from 6.7 months to 13.2 months median survival represents, in tangible human terms, nearly seven additional months at home with family. For a disease that has operated under the weight of its prognosis for forty years, that is a meaningful beginning. The RAS revolution arrived at ASCO 2026. It will not stop with pancreatic cancer.

Sources: ASCO 2026 Plenary Presentation, RASolute 302 Clinical Trial (NCT06625320); New England Journal of Medicine, Phase 1/2 daraxonrasib data, May 2026; Dana-Farber Cancer Institute press release, May 31, 2026; ASCO official press release, May 31, 2026; JAMA Oncology, dietary inflammatory index and PDAC risk, 2022.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.